MindwaysCT receives FDA clearance for bone mineral density measurement technology

MindwaysCT received 510(k) clearance from the U.S. Food and Drug Administration to market its quantitative computed tomography calibration technology for CT-based bone mineral density measurement.

Advertisement

MindwaysCT’s latest QCT software innovation makes it possible to assess bone mineral density using QCT without the need to scan a calibration phantom together with the patient. The new technology can also offer retrospective analysis of previously acquired images.

More articles on devices:

aap Implantate receives patent for LOQTEQ
NuVasive COO sells 2.5k shares in $87k transaction
$0.9B by 2019: 3D printing in medical applications market analysis

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Orthopedics

Advertisement

Comments are closed.